Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PhytoMedical and Medicilon Seek China Partner for Cancer Drug

publication date: Apr 15, 2010
PhytoMedical Technologies, Inc. of Princeton, NJ, has signed a letter of intent with Shanghai Medicilon, a preclinical CRO. Under the terms of the proposed agreement, Medicilon will seek to find a China partner for PhytoMedical’s pre-clinical cancer compound. The price for the China rights to the drug will be payment for the compound’s pre-clinical development, which will be conducted by Medicilon. PhytoMedical and the partner will each be responsible for submitting the IND package to their respective agencies. More details...

Stock Symbol: (OTCBB: PYTO)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital